Altimmune (ALT)

• Market cap: $513M
• 1 day: 1.15%
• 5 days: -4.69%
• 1 month: -7.37%
• 3 months: -27.07%
• 6 months: -50%
• Year to date: -24.79%
• 1 year: -61.57%
• 5 years: -81.32%
• 10 years: -99.61%
• Sector: Healthcare
• Industry: Biotechnology

About: Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Employees: 57